The Association for Clinical Oncology (ASCO) along with other health care organizations sent a letter to U.S. Senate leadership to convey their opposition to an extension of mandatory Medicare sequestration as a pay-for in any infrastructure package. The letter urges lawmakers to reconsider the potential use of Medicare funds included in the bipartisan infrastructure framework.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
Members of Congress recently reintroduced the Cancer Drug Parity Act (H.R. 4385) in the U.S. House of Representatives. The bill would ensure patient cost sharing for oral and other self-administered anticancer drugs is no less favorable than for traditional intravenous (IV) medication administered in an office setting.
The Centers for Medicare & Medicaid Services (CMS) released its 2022 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Specific provisions that would impact the cancer care community are included here.
ASCO provided comments on a recently released 21st Century Cures 2.0 Act discussion draft and accompanying Advanced Research Projects Agency Health (ARPA-H) request for information (RFI).
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today announced that 75 research sites applied and have been invited to participate in a pilot project testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity among clinical trial participants.
The Association for Clinical Oncology (ASCO) is calling on Congress to continue their bipartisan support of federally funded research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) baseline budgets are critical in advancing our nation’s work towards combating, and ultimately curing, diseases like cancer.
On July 13, 2021, the Centers for Medicare & Medicaid Services released its proposed rule for the 2022 Medicare Physician Fee Schedule and updates to the Quality Payment Program (QPP). The Association for Clinical Oncology (ASCO) is still analyzing the full proposal, but based on a preliminary analysis, key provisions for the cancer care community are included here.
Today, the American Society of Clinical Oncology (ASCO) and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards, which provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence-based cancer care.
In addition to the Association for Clinical Oncology’s (ASCO) advocacy at the federal level in Washington, DC, ASCO is also at work in state capitals advocating for improved patient access to high-quality, equitable cancer care at the state level. Cancer policy advancements at the state level have recently occured in Arizona, Pennsylvania, and Oregon.
The Department of Health and Human Services (HHS), the Department of Labor, the Department of the Treasury, and the Office of Personnel Management released an interim final rule with comment period (IFR), Requirements Related to Surprise Billing; Part I. This rule is the first of a series that will implement provisions of the No Surprises Act (NSA) signed into law as part of the 2021 COVID-19 relief bill.
The Association for Clinical Oncology (ASCO) submitted comments to the Centers for Medicare & Medicaid Services in response to two cancer-related provisions in the 2022 Medicare Hospital Inpatient Prospective Payment System (IPPS) proposed rule. ASCO’s comments include responses to CMS’ Requests for Information (RFIs) on the transition to digital quality measures and health equity.
Delegates from the Association for Clinical Oncology (ASCO) participated in a Special Meeting of the American Medical Association’s (AMA) House of Delegates (HOD), where the HOD voted to approve two ASCO-backed resolutions.
In a joint position statement, ASCO and Friends of Cancer Research say individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion.
The U.S. Department of Health and Human Services (HHS) released revised reporting requirements for recipients of Provider Relief Fund (PRF) payments. Updates include expanding the amount of time providers will have to report information, efforts to reduce burdens on smaller providers, and extending key deadlines for expending PRF payments for recipients who received payments after June 30, 2020.
A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation.